Ultragenyx Pharmaceutical (RARE) Current Deferred Revenue (2013 - 2019)
Ultragenyx Pharmaceutical (RARE) reported Current Deferred Revenue of $69000.0 for Q1 2019, down 90.46% year-over-year from $723000.0 in Q1 2018, and down 94.45% quarter-over-quarter from $1.2 million in Q2 2018.
Ultragenyx Pharmaceutical (RARE) Current Deferred Revenue (2013 - 2019) Analysis & Trends
Ultragenyx Pharmaceutical (RARE) has 7 years of Current Deferred Revenue data on file, last reported at $69000.0 in Q1 2019.
- Current Deferred Revenue for Q1 2019 came in at $69000.0, down 90.46% year-over-year; the trailing twelve-month figure through Mar 2019 was $69000.0 (down 90.46% YoY), and the FY2017 annual result was $6.0 million, up 1655.43% from the prior year.
- Current Deferred Revenue declined to $69000.0 in Q1 2019 per RARE's latest filing, from $1.2 million in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $6.0 million in Q4 2017 and troughed at $69000.0 in Q1 2019.
- A 5-year average of $794000.0 and a median of $328000.0 in 2016 frame the typical range for Current Deferred Revenue.
- The sharpest annual moves came in 2017 and 2019: Current Deferred Revenue soared 1655.43% in 2017, then tumbled 90.46% in 2019.
- A 5-year view of Current Deferred Revenue shows it stood at $192000.0 in 2015, then jumped by 77.6% to $341000.0 in 2016, then soared by 1655.43% to $6.0 million in 2017, then plunged by 79.22% to $1.2 million in 2018, then slumped by 94.45% to $69000.0 in 2019.
- Business Quant data shows RARE's Current Deferred Revenue at $69000.0 in Q1 2019, $1.2 million in Q2 2018, and $723000.0 in Q1 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Ultragenyx Pharmaceutical | 2.77 Bn | 2.36 Bn | 106.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2019 | 69,000.00 |
| Jun 30, 2018 | 1.24 Mn |
| Mar 31, 2018 | 723,000.00 |
| Dec 31, 2017 | 5.99 Mn |
| Sep 30, 2017 | 695,000.00 |
| Jun 30, 2017 | 669,000.00 |
| Mar 31, 2017 | 637,000.00 |
| Dec 31, 2016 | 341,000.00 |
| Sep 30, 2016 | 328,000.00 |
| Jun 30, 2016 | 315,000.00 |
| Mar 31, 2016 | 303,000.00 |
| Dec 31, 2015 | 192,000.00 |
| Sep 30, 2015 | 163,000.00 |
| Jun 30, 2015 | 155,000.00 |
| Mar 31, 2015 | 90,000.00 |
| Dec 31, 2014 | 85,000.00 |
| Sep 30, 2014 | 80,000.00 |
| Jun 30, 2014 | 75,000.00 |
| Mar 31, 2014 | 78,000.00 |
| Dec 31, 2013 | 78,000.00 |